The inhibition of the cholesteryl ester transfer protein (CETP) provides a method for the elevation of the high density lipoprotein cholesterol (HDL-C) level, i.e. the 'good' cholesterol. The expected anti-atherogenic effect
of this approach is independent of the proven benefits of lowering the low density lipoprotein cholesterol (LDL-C) level, i.e. the 'bad' cholesterol. A medicinal chemistry project is presented starting from the first screening hit to the second generation
development candidate. The structure–activity relationship, the syntheses and the role of fluorine during optimization, as well as the biological activities are discussed.
胆固醇酯转移蛋白(CETP)的抑制提供了一种提高高密度脂蛋白胆固醇(HDL-C)水平的方法,即“好”胆固醇。这种方法预期的抗动脉粥样硬化效果独立于降低低密度脂蛋白胆固醇(LDL-C)水平的已证实益处,即“坏”胆固醇。从第一次筛选命中到第二代开发候选药物的药物化学项目被呈现出来。讨论了结构活性关系,合成和氟在优化过程中的作用,以及生物活性。